Pharmaceuticals News and Research

RSS

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations for the production of sustainable biochemicals, today exchanged definitive agreements with Malaysian Bio-XCell for the establishment of the Company's industrial biochemical plant and biotechnology R&D facility in Malaysia

1 Nov 2010

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex drugs, today announced its financial results for the quarter ended September 30, 2010.

1 Nov 2010

Aegerion underwriters exercise over-allotment option

Aegerion Pharmaceuticals, Inc. today announced that the underwriters of its October 22, 2010 initial public offering have exercised in full their over-allotment option to purchase an additional 750,000 shares of Aegerion's common stock at $9.50 per share, less underwriting discounts and commissions. The option was granted in connection with Aegerion's initial public offering of 5,000,000 shares. The over-allotment option is expected to close on November 2, 2010, subject to customary closing conditions.

1 Nov 2010

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Nycomed today announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in the research, development, manufacturing and marketing of biologic drugs derived from natural sources.

1 Nov 2010

Endo third quarter total revenues increase 23% to $444.1 million

Endo Pharmaceuticals today reported financial results for the third quarter 2010.

1 Nov 2010

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that on Friday, October 29, 2010 it submitted a complete response to the "Complete Response" letter issued by the U.S. Food and Drug Administration (FDA), regarding its supplemental New Drug Application (sNDA) for FUSILEV (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

1 Nov 2010

Global Genes Project launches new campaign to create awareness about rare diseases

The Global Genes Project, a non-profit advocacy organization that aims to raise awareness about the prevalence of rare diseases worldwide, today launched the 7,000 Bracelets for Hope campaign. The 7,000 Bracelets for Hope campaign is designed to draw attention to an estimated 7,000 different chronic, life-threatening and fatal rare diseases and disorders affecting approximately 30 million Americans and millions more globally.

1 Nov 2010

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst Pharmaceutical Partners, Inc. today announced positive results from a series of CPP-115 preclinical safety and efficacy evaluations. CPP-115 was found to have a significantly improved retinal safety profile compared to vigabatrin.

1 Nov 2010

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

As the champagne corks are popping this New Year's Eve, the first American Baby Boomers will turn age 65. Members of the demographic bulge that transformed American politics and culture are expected to usher in yet another momentous change a huge increase in the number of Alzheimer's disease patients.

1 Nov 2010

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Vertex Pharmaceuticals Incorporated today announced new data from its Phase 3 studies of people with genotype 1 chronic hepatitis C who have not been treated previously. In these studies, the majority of people achieved superior sustained viral response (SVR or viral cure) rates with a telaprevir-based combination regimen, compared to current therapies, regardless of race/ethnicity or stage of liver fibrosis (factors known to limit response to current hepatitis C treatments).

1 Nov 2010

Dyadem opens second office to meet customer demand for enterprise risk management software

Dyadem today announced the opening of its second office in Europe; located in Starnberg, Germany, on the outskirts of Munich. Dyadem, the leader in Operational and Quality Risk Management, has expanded in response to a surge in customer demand in the European Union for its enterprise risk management software and services amid heightened scrutiny of safety and quality standards for companies in the oil & gas, chemical, medical device and pharmaceutical industries.

1 Nov 2010

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Shield Holdings AG (Shield), the independent specialty pharmaceutical company focused on the development and commercialisation of late-stage hospital pharmaceuticals, today announces that it has signed a strategic commercialisation agreement for its lead asset, ST10-021, an iron therapy product which has commenced Phase III clinical development, with AOP Orphan Pharmaceuticals AG.

1 Nov 2010

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Medivir AB, the research-based speciality pharmaceutical company focused on the development of high-value treatments for infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, has announced the results of a Week-24 planned interim analysis of the Phase 2 response-guided PILLAR study for TMC435, Medivir's key pipeline asset, a hepatitis C protease inhibitor dosed once-daily.

1 Nov 2010

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a Phase 1 clinical trial evaluating IMO-2125, a novel immune modulator, in null-responder patients with chronic hepatitis C virus (HCV) infection.

1 Nov 2010

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Salix Pharmaceuticals, Inc. today announced that the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2010) will be an important venue for ongoing discussion of hepatic encephalopathy, or HE.

1 Nov 2010

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

Tibotec Pharmaceuticals announced today the company will present the results of a Week-24 planned interim analysis of the phase 2 response-guided PILLAR study in treatment-naive patients with chronic genotype 1 hepatitis C virus (HCV) at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA., USA. The data will be presented as part of a late-breaker oral presentation on Monday, November 1.

1 Nov 2010

FDA approves Afinitor drug for tuberous sclerosis complex

The Tuberous Sclerosis Alliance (TS Alliance) today announced the first drug approved for a tuberous sclerosis complex (TSC) indication by the Federal Drug Administration (FDA). This drug, manufactured by Novartis Oncology, is called Afinitor and will be used to treat subependymal giant cell astrocytomas (SEGAs) in individuals with TSC.

1 Nov 2010

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

Anadys Pharmaceuticals, Inc. today announced the ANA598 data to be presented at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) in Boston, MA.

1 Nov 2010

FDA new approvals, antibiotic and neurological drugs

Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.

31 Oct 2010

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

The 2010 Mid-Atlantic Bio today completed another successful conference hosting 728 registrants from 22 states and 4 countries, with more than 400 companies and 50 qualified investors participating. Dedicated to promoting the biotechnology industry in the Mid-Atlantic region, the conference is hosted collectively by the region's most influential bioscience and investor associations, the Mid-Atlantic Venture Association (MAVA), the Tech Council of Maryland/MdBio (MdBio) and the Virginia Biotechnology Association (VaBIO).

30 Oct 2010

Pharmaceuticals News and Research

GlycosBio, Malaysian Bio-XCell enter agreement to build biochemical plant and biotechnology R&D facility

Momenta reports $32.1M net income for third quarter 2010 vs. $14.6M net loss for third quarter 2009

Aegerion underwriters exercise over-allotment option

Nycomed acquires majority stake in Guangdong Techpool Bio-Pharma

Endo third quarter total revenues increase 23% to $444.1 million

Spectrum submits complete response to FDA's CRL for FUSILEV to treat colorectal cancer

Global Genes Project launches new campaign to create awareness about rare diseases

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

America's biopharmaceutical companies researching 98 medicines for Alzheimer's: PhRMA report

Vertex reports superior SVR rates with telaprevir-based combination therapy in Phase 3 studies for hepatitis C

Dyadem opens second office to meet customer demand for enterprise risk management software

Shield signs strategic commercialization agreement for ST10-021 iron therapy product

Medivir's partner Tibotec reports Week 24 interim results from TMC435 Phase 2b study in HCV

Idera presents IMO-2125 Phase 1 clinical trial data for HCV infection at AASLD Meeting

Salix to discuss XIFAXAN therapy for hepatic encephalopathy at AASLD 2010 Annual Meeting

Tibotec to present Week-24 interim analysis of PILLAR study for chronic HCV treatment at AASLD Meeting

FDA approves Afinitor drug for tuberous sclerosis complex

Anadys presents data of ANA598 for hepatitis C treatment at AASLD Annual Meeting

FDA new approvals, antibiotic and neurological drugs

2010 Mid-Atlantic Bio a great kick-off for hosting 2011 BIO International Convention

Event guide: World ADC London eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence